Bruce Davis joins LeukoDx
This article was originally published in Clinica
Point-of-care diagnostics company LeukoDx (Towson, Maryland) has appointed Bruce Davis chief scientific officer. Dr Davis is the founder and president of Trilium Diagnostics, which is developing diagnostics assays for clinical cytometry and lab haematology. LeukoDx has also licensed a patent and technology from Trilium regarding quantifying CD64. The latter's CD64 test kits are CE marked for sale in Europe, and awaiting US FDA approval. LeukoDx plans to make CD64 the first biomarker to be used in its disposable test cartridge for diagnosing and monitoring sepsis, which will run on its point-of-care flow cytometry platform. The company is also developing tests for detecting urinary tract infection, and monitoring HIV progression and treatment.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.